ASH Standing Committee Update
Drs. Sherif Badawy, Michael Linenberger, and Joseph Mikhael provide an overview of three ASH standing committees including each group's goals, mission, and new developments
Combining Daratumumab With Backbone Antimyeloma Agents
Dr. Raje reviews a study that compares daratumumab, lenalidomide, and dexamethasone with lenalidomide and dexamethasone alone for the treatment of patients with multiple my
ASH is in the initial stage of the selection process for the next Editor-in-Chief of The Hematologist (term:2018-2020).
Dr. Hoggatt and Dr. Chou discuss a study that reviews efforts to expand the numbers of human CD34+ cells for transplantation.
Dr. DeBaun covers a trial that provides reasonable data for advancing care of children with hemoglobinopathies.
September/October 2016 Volume 13, Issue 5
View all Features articles
View all Diffusion articles
Dr. Charles Abrams talks about the importance of ASH's effort to promote diversity through its Minority Recruitment Initiative's programs.
View all president's column articles
View all Ask the Hematologist articles
View all Op-Ed articles
View all Mini Review articles
The Cancer Moonshot Blue Ribbon Panel recently released a report highlighting 10 key research opportunities that should be supported by the Cancer Moonshot initiative to accelerate progress against cancer. ASH submitted recommendations to the Panel in response to the National Cancer Institute’s request for information on high priority areas that should be supported by this initiative.
The National Heart Lung and Blood Institute (NHLBI) has released its strategic vision which highlights the goals and research priorities that will inform its policy and funding decisions for heart, lung, blood, and sleep diseases (HLBS) in the next several years. ASH participated in the NHLBI’s strategic visioning process and submitted additional comments when the NHLBI’s draft strategic priorities were released.
The Centers for Medicare and Medicaid Services (CMS) released the annual set of proposals governing payments for services provided to patients admitted to the hospital, commonly referred to as the hospital inpatient prospective payment system (IPPS). ASH explores how this will affect hematologists.
As part of the American Society of Hematology’s (ASH)
multifaceted initiative to address the burden of sickle cell disease, ASH is in
the process of working with stakeholders to improve access to care for
individuals with sickle cell disease.
Included in this effort is
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology